… to negotiate prices of drugs directly with pharmaceutical companies.3 Previously, all … Pharmaceuticals) Apalutamide (Erleada; Johnson & Johnson) Ribociclib (Kisqali; Novartis) Lenvatinib (Lenvima; Eisai …

… in commercialization of the drug with partner Otsuka Pharmaceutical. The Centers for … PhRMA attributes high drug costs to insurers and pharmacy benefit managers (PBMs … — breast cancer, Novartis Lenvima — cancer, Eisai and Merck Orencia — inflammatory disorders …

… Pharmaceuticals) Erleada (apalutamide; Janssen Biotech) Kisqali (ribociclib; Novartis) Lenvima (Lenvatinib mesylate; Eisai … renegotiation. Negotiations with participating drug companies will occur in … and distribution for selected drugs—are also taken into …

… New Jersey pharmaceutical giants are among the next 15 prescription drugs targeted … ; as well as cancer drug Lenvima from Eisai and Merck. Under the … relationship with Medicaid. Despite the pharmaceutical industry’s longstanding opposition to …

… Food and Drug Administration (FDA) has accepted Eisai’s Supplemental … mg subcutaneous dosing achieved drug exposure comparable to … -weekly IV treatment. Eisai leads global development and … submissions for lecanemab, while Eisai and Biogen jointly commercialize …

… chronic obstructive pulmonary disease drug, Anoro Ellipta (umeclidinium … breast cancer. Takeda Pharmaceutical Company Ltd’s (NYSE … :JNJ) prostate cancer drug Erleada (apalutamide) Eisai Co. Ltd.’s … conditions. The selected drug for renegotiation is:  …

… data on those drugs.  Six of drugs are often administered … (Novartis) Lenvima, advanced cancers. (Eisai) Orencia, rheumatoid arthritis and psoriatic … Myers Squibb) Rexulti, schizophrenia. (Otsuka Pharmaceuticals) Trulicity, cardiovascular diseases. (Eli …

… breast cancer medicine Kisqali, Eisai's cancer therapy Lenvima … Tradjenta for renegotiations. The drug was previously included in last … rather than obtained at pharmacies. The move comes shortly … of the year. The pharmaceutical industry has wagered a public …

Eisai and Biogen have announced that the US Food and Drug Administration … FDA has set a Prescription Drug User Fee Act (PDUFA … treatment for 18 months. Eisai leads global development and … responsibilities. In November 2025, Eisai and Biogen announced the …

… origin drugs approved to be imported in 2025 includes AstraZeneca Pharma India … Pvt. Ltd’s Marstacimab, and Eisai Pharmaceuticals India Pvt. Ltd’s Lecanamab … weight loss, including prescription drugs, over-the- counter drugs, and herbal preparations …